In short. Sorting the group by evidence: a few have trials behind them, most have histology or laboratory work, and some have nothing at all.
Key points
- Histology and laboratory measurement are how investigations begin.
- A result is what happens in people, measured over time, against a comparison.
- Where only the first exists, the second is being inferred, and the inference is where the claim grows larger than the evidence.
The evidence in this category is not one body of work. It is a range, from controlled studies at one end to nothing at all at the other, and sorting the group along that range is the most useful thing this site does.
The top of the range
A small number of materials are approved for named uses, and those approvals rest on assessment for a defined purpose in a defined population. This is the strongest position anything in the group occupies, and it applies to a material and a use rather than to a class. A blood-derived preparation made from the patient’s own blood has more clinical studies than anything else grouped here, several with a comparison group, and the results disagree with one another, which makes it the strongest clinical evidence in a group where that is a relative statement.
The middle of the range
A good deal of what is offered rests on histology and laboratory work. A tissue sample showing a response establishes that a process occurred. A measurement in a dish showing that something is released establishes that it is present. Neither establishes the size of any change in a person, whether it is visible, or whether it would be recognised as an improvement. This is real evidence and it is evidence of the wrong thing, which is the most common difficulty in this subject.
A process observed is not a result achieved
Histology and laboratory measurement are how investigations begin. A result is what happens in people, measured over time, against a comparison. Where only the first exists, the second is being inferred, and the inference is where the claim grows larger than the evidence.
The bottom of the range
Some products in this group have no controlled studies, no authorisation and no long-term data. What they have is a mechanism, a name and a description, and in some cases a warning from a regulator about how they are advertised. For those, the evidence question is not how strong the evidence is but whether any exists, and the honest answer is that it does not.
Why the range is so wide
Because the studies that would settle these questions are long and expensive, and because a product sold outside approval is not required to have any. Where nobody is obliged to demonstrate an effect, the demonstration tends not to happen, and the gap between the strongest and weakest members of the group widens rather than closes.
How to place a claim on the range
- Is there an authorisation for this use, and does the claim stay inside it?
- Is the evidence a controlled study in people, a tissue or laboratory finding, or a mechanism?
- Has anybody independent of the seller reproduced it?
Placing a claim on that range takes a few questions and it is the difference between a treatment with a documented basis and one with a description.
Frequently asked questions
Which claims in this group have the strongest evidence?
The regulatory facts, which are not clinical findings but are the most solid thing available: that a small number of materials are approved for named uses and that cell and exosome products generally are not. On the clinical side, a blood-derived preparation has the most studies and they are mixed.
What is histology evidence worth?
It establishes that a process occurred in a tissue sample. It does not establish the size of any change, whether it is visible, or whether a person would recognise it. A tissue finding is the beginning of the reasoning rather than a result, and it is often presented as the end of it.
Why is so much of the evidence early?
Because the studies that would settle the questions are long and expensive, and products are often renamed or replaced before such a study could finish. Where a product is sold outside approval, nobody is required to run the study in the first place, which is why the gap persists.
Risks & Limitations
- The word regenerative describes a marketing position rather than an approved class, and no authority approves a material as regenerative.
- Cell and exosome products are generally not approved as cosmetic treatments, and warnings have been issued about advertising them as treatments.
- Most injected cells do not survive in useful numbers, which is the step that a claim of tissue rebuilding depends on.
- An absence of reported harm in an unapproved product is an absence of reporting rather than a finding of safety.
- A point-of-care preparation carries a risk of infection introduced during preparation, because blood handled outside a controlled laboratory is a medium in which bacteria grow.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after a procedure.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- Any new and persistent symptom after a procedure, or a change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — warnings and guidance on unapproved cell and exosome products
- European Medicines Agency (EMA) and national regulators — advanced therapy classification and guidance
- National Medical Products Administration (NMPA, China) — approved biological products and their indications
- World Health Organization (WHO) — guidance on cell and tissue-based therapies and their oversight
- Cochrane Library — systematic reviews of cell-based and platelet treatments for skin indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.